LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, today announced the arrival1 of Jean Zetlaoui on Valbiotis’ Supervisory Board1.
“We look forward to welcoming Jean Zetlaoui on our Supervisory Board. He is a man of action and a recognized pharmaceutical and nutrition expert. He will be a strong addition to an already highly qualified team of internationally recognized experts, and his considerable experience in these key complementary areas for VALBIOTIS will be a great advantage for our company’s development. VALBIOTIS does business with major pharmaceutical and nutrition corporations which gives us a unique, high-added-value positioning. Zetlaoui’s arrival will further reinforce this positioning,” said VALBIOTIS CEO Sébastien Peltier.
Existing members of the VALBIOTIS Supervisory Board include:
- Mr. Laurent Levy (PhD), Chairman of VALBIOTIS’ Supervisory Board and Chairman of the Board of Directors of NANOBIOTIX (ISIN code FR0011341205);
- Mr. Sébastien Bessy, Member of VALBIOTIS’ Supervisory Board and Vice-President Global Marketing & Portfolio Strategy of IPSEN Global PCBU;
- Mr. Philippe Vuagnat (PhD), Member of VALBIOTIS’ Supervisory Board and CEO of SOFIMAC Partners.
“VALBIOTIS has a unique ‘Nutrition Healthcare’ positioning. By developing preventive solutions and providing nutritional support for cardiometabolic diseases, VALBIOTIS is delivering a strong message, in particular by tackling pre-diabetes which affects some 130 million people in the European and American markets alone. I am convinced that the company has everything it takes to become a world reference and I look forward to contributing to its business development,” said Dr. Jean Zetlaoui.
Jean Zetlaoui has over 25 years’ experience in various managerial posts abroad and is bringing his advanced knowledge of the pharmaceutical and nutrition sectors, of their environments and their challenges.
He has been Scientific Director of NOVARTIS Pharma SAS since January 2014, is a member of the Executive Committee and was also Chief Medical Officer and member of the Nestlé Health Science Executive Committee in Vevey, Switzerland, for 2 years, contributing to the growth of personalized medicine and health nutrition related business. Over the past 20 or so years, Zetlaoui has also held various managerial and R&D positions at SANOFI, including those of Vice-President Head of Market Access, Vice-President Head of Global Regulatory Affairs and Vice-President Deputy Head of Global Medical Affairs.
Jean Zetlaoui is also Vice-President of the Alliance for Research and Innovation in Health Industries (ARIIS) and Chairman of the working group on the attractiveness of France for clinical research headed by Leem, an association of French pharmaceutical companies.
Before joining the pharmaceutical industry, Dr. Jean Zetlaoui worked as a hospital practitioner at Bicêtre CHU.
Zetlaoui holds a medical degree and a specialization in anesthesia and resuscitation. He has also completed an Executive MBA in Finance and International Business at the ESSEC Business School (1991).
VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
Valbiotis was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. Valbiotis is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).
Find out more about VALBIOTIS:
ISIN code: FR0013254851
Mnemonic code: ALVAL
1 The appointment of Dr. Zetlaoui will be put forward at the Annual General Meeting to be held October 26th, 2017, at 2 pm on the 6th floor of the offices of the law firm Granrut, 91 rue du Faubourg Saint-Honoré, 75008 Paris.